Zhejiang Anglikang Pharmaceutical Co., Ltd. announces the resolutions of its 20th Board of Directors meeting. The board approved exempting the notice period for the meeting and an investment of RMB 50 million in Shengshi Kang Bio-medicine (Hangzhou) Co., Ltd., acquiring a 36.4706% stake and priority cooperation rights for R&D products in Greater China.
Summary generated by AI · Always verify with source document
Securities Code: 002940
Securities Abbreviation: Anglikang
Announcement Number: 2026-061
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Announcement on the Resolutions of the 20th Meeting of the Fourth Board of Directors
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.